Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06441214
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-04
First Post:
2024-05-15
Brief Title:
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenströms Macroglobulinemia WM Treated in Italy According to the Zanubrutinib Brukinsa Compassionate Use Program CUP and in Common Practice Following Commercial Approval
Sponsor:
Fondazione Italiana Linfomi - ETS
Organization:
Fondazione Italiana Linfomi - ETS
Study Overview
Official Title:
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenströms Macroglobulinemia WM Treated in Italy According to the Zanubrutinib Brukinsa Compassionate Use Program CUP and in Common Practice Following Commercial Approval
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a non-interventional observational retrospective and prospective multicenter Italian study to describe treatment management and outcomes of Waldenströms Macroglobulinemia WM patients treated according to the Italian Compassionate Use Program CUP and receiving zanubrutinib following its commercial approval
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None